glp 1 agonist and dementia GLP-1 Medications Associated with Reduced Likelihood of Compared to Other Diabetic Meds NEW STUDY: GLP-1 meds slash
Description
The SOUL cardiovascular outcomes trial (CVOT) demonstrated a 14% relative reduction in risk of MACE in patients treated with Rybelsus 14 mg orally once daily for approximately 5 years compared to those who received placebo
In contrast, certain studies and reports have indicated that there were not any significant differences between general perioperative adverse outcomes (Raven et al
Dapagliflozin in patients with chronic kidney disease
Once you understand the core ideas, though, they are actually quite straightforward
